Darren Bryan

Thoracic surgeon at the University of Chicago @UChicagoCTSurg. @BrighamThoracic @uchicagosurgery @MacLeanEthics alum. Husband of/inspired by: @avafbryan

[Darren Bryan @DSBryan1]

@ErinGillaspie @VUMChealth @WomenInThoracic @womeninsurgery @WomenSurgeons Congratulations! Best of luck!

[Darren Bryan @DSBryan1]

@JackWestMD @BrendonStilesMD Big fan the term “aspirationally resectable”

And, agree. Need to focus on meeting current standards for high quality lung cancer surgery. But as a field, we should still have certain people pushing the boundaries. Doing so shouldn’t distract from high quality surgery, everywhere

[Selwyn O. Rogers Jr. @selwyn_rogers]

Aren’t You the Valet? Tales of Black American Surgeons | NEJM Today, in the US, it is as if there are 2 different scripts being loudly declaimed trying to drown each other out. The escalating chant “BLM” is countered by … cancel culture & White supremacy. https://t.co/3VKmh4OD5H

[Darren Bryan @DSBryan1]

5 year follow up from a 2018 phase-II pilot study of neoadj. nivolumab (https://t.co/GPaONNkeEs). Impressive outcomes!

https://t.co/UPBeLfpMpB

[Patrick Forde @FordePatrick]

And here is a graphic of the five year outcomes!

[Farhood Farjah @FarhoodFarjah]

Thank you for sharing your experience!

Hearing my patients’ stories over the years during surveillance has led me to believe (even though i cannot prove) that PFTs have value in risk-stratification, but they do not predict patient experience.

[Darren Bryan @DSBryan1]

@FarhoodFarjah @ElliotServaisMD @ekslim @JVelottaMD @DrYolondaColson @DoctorJSpicer @DouglasEWood1 @EADavidMD @ErinGillaspie @ewakeam @girlceppa @hari_keshava @Howington8John @IanCBostock1 @jdoningtonmd @jdphillipsMD @rjmehran @JulesLin99 @katberfieldMD Also curious about this. In fellowship our pathologists would regularly and it would help guide decision making. Particularly with STAS (though recognizing the difficulty to call it on a frozen specimen)

[Eric Lim @ekslim]

Delighted to announce MARS 2 data is now mature and we aim to report this year! Thank you to our patients, UK investigators, @BrsTrialsCentre, @NIHRresearch @CRUKresearch for 7 years of hard work!!

[Darren Bryan @DSBryan1]

💯
Well said. Couldn’t agree more.
#tssmn #MedEd #SurgEd

[Farhood Farjah @FarhoodFarjah]

@SethBKrantz @DSBryan1 @ElliotServaisMD @DavidCookeMD @TomVargheseJr @DrShawnGroth @BrendonStilesMD @ShandaBlackmon @LindaMThoracic Agree with a disease-based rather than procedure-based approach to knowledge acquisition for the subspecialist surgeon practicing non-cardiac thoracic surgery.

[Darren Bryan @DSBryan1]

@ElliotServaisMD @DavidCookeMD @TomVargheseJr @DrShawnGroth @BrendonStilesMD @ShandaBlackmon @LindaMThoracic Fascinating time to be in this field!

5 all time:

Z0030
CROSS
NLST
PACIFIC
CM816

5 in the last 5 years (interested to see how others place these in the all-time list)

CM 816
CM 577
ADAURA
Impower010
NADIM

[Darren Bryan @DSBryan1]

Here here! Congratulations @JBMatthews! So well deserved.

[UChicago Surgery @uchicagosurgery]

CONGRATULATIONS, Dr. Matthews! From all of us, we are lucky to call your our Chair! 🎉

@JBMatthews @UnivSurg @AcademicSurgery #ASC2023

[Henning Willers, MD, FASTRO @HenningWillers]

AUDARA update with longer F/U but OS data still withheld https://t.co/msig4NFFKL

Interesting👀 Brain mets incidence starts to rise AFTER 3 years osi is up in stage II/IIIA while in control group it plateaus at ~10%. So does osi really only delay recurrence?🧐

Do we need MRIs???

[Mark Sorin @sorin_mark]

Importantly, for clinical relevance, we show that we can predict recurrence after surgery in a cohort of Stage 1A-B lung cancer patients by using machine learning and as a result can inform on adjuvant treatment strategies. We don’t need 35 markers- we can do this with just 6! 🙌🏼

[Darren Bryan @DSBryan1]

@haroldpollack @politico That’s it! Thanks

[Jeff Matthews MD @JBMatthews]

Dr John Alverdy’s last day in the OR after 30 years at @uchicagosurgery Thousands of patients have benefited from his expertise, and his legacy includes hundreds of trainees - THE BEST. #ThankYou @UChicagoMed #EndOfAnEra #TheLegend #NewChapter #HesNotGoingAnywhere

[Jonathan Spicer MD PhD @DoctorJSpicer]

@esinghimd @ADesaiMD @FDAOncology @DrSteveMartin @n8pennell @JackWestMD Here’s some help: just do neoadj and you’ll hardly ever have to think about this adj business. The real question is whether there’s value in adj IO for patients who received neoadj chemo-IO. That’s the real question for which we will soon have some useful data. #LCSM

[donington @jdoningtonmd]

I am incredibly appreciative to be at an institution that values diversity and equity. I am proud of the work we do to combat structural racism and improve access to care. @UChicagosurgery promotes a positive and inclusive environment

[Darren Bryan @DSBryan1]

@KateEEngelhardt Here here!

[Abby White, DO @AbbyWhiteDO1]

Issue Information ‐ TOC https://t.co/d31LzCcDmc

This month's issue of JSO puts the spotlight on thoracic oncology and our own Dr. Mike Jacklitsch @BrighamSurgery @BrighamThoracic

[Darren Bryan @DSBryan1]

@DrRianCharles @jdphillipsMD @TOutcomes @STS_CTsurgery @DartSurgery @DartmouthCancer @DartmouthHealth Important topic! Couldn’t be there this year but looking forward to seeing the manuscript